Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

March 13, 2020

Study Completion Date

July 24, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

REGN3500

Administered subcutaneous (SC)

DRUG

REGN3500-Matching Placebo

Administered subcutaneous (SC)

Trial Locations (89)

2217

Regeneron Study Site, Kogarah

3002

Regeneron Study Site, Melbourne

4032

Regeneron Study Site, Debrecen

5900

Regeneron Study Site, Orosháza

10022

Regeneron Study Site, New York

10117

Regeneron Study Site, Berlin

12459

Regeneron Study Site, Berlin

14004

Regeneron Study Site, Córdoba

14584

Regeneron Study Site, Bucheon-si

15706

Regeneron Study Site, Santiago de Compostela

16499

Regeneron Study Site, Gyeonggi-do

20537

Regeneron Study Site, Hamburg

21431

Regeneron Study Site, Incheon

21565

Regeneron Study Site, Incheon

23502

Regeneron Study Site, Norfolk

23538

Regeneron Study Site, Lübeck

28041

Regeneron Study Site, Madrid

28405

Regeneron Study Site, Wilmington

29420

Regeneron Study Site, North Charleston

31217

Regeneron Study Site, Macon

32256

Regeneron Study Site, Jacksonville

35209

Regeneron Study Site, Birmingham

40202

Regeneron Study Site, Louisville

40217

Regeneron Study Site, Louisville

40241

Regeneron Study Site, Louisville

45231

Regeneron Study Site, Cincinnati

47714

Regeneron Study Site, Evansville

48149

Regeneron Study Site, Münster

48455

Regeneron Study Site, Bad Bentheim

48903

Regeneron Study Site, Barakaldo

49085

Regeneron Study Site, Saint Joseph

49241

Regeneron Study Site, Busan

49477

Regeneron Study Site, Ibbenbueren

55402

Regeneron Study Site, Minneapolis

58453

Regeneron Study Site, Witten

60077

Regeneron Study Site, Skokie

60590

Regeneron Study Site, Frankfurt

63450

Regeneron Study Site, Hanau

66215

Regeneron Study Site, Overland Park

72076

Regeneron Study Site, Tübingen

72205

Regeneron Study Site, Little Rock

73071

Regeneron Study Site, Norman

78218

Regeneron Study Site, San Antonio

78229

Regeneron Study Site, San Antonio

78258

Regeneron Study Site, San Antonio

80337

Regeneron Study Site, München

85006

Regeneron Study Site, Phoenix

85259

Regeneron Study Site, Scottsdale

85718

Regeneron Study Site, Tucson

89148

Regeneron Study Site, Las Vegas

90404

Regeneron Study Site, Santa Monica

92056

Regeneron Study Site, Oceanside

92708

Regeneron Study Site, Fountain Valley

94538

Regeneron Study Site, Fremont

95815

Regeneron Study Site, Sacramento

03756

Regeneron Study Site, Lebanon

T2G 1B1

Regeneron Study Site, Calgary

L8S 1G5

Regeneron Study Site, Hamilton

L8S 4K1

Regeneron Study Site, Hamilton

M5N 1E3

Regeneron Study Site, Toronto

N8X 2G1

Regeneron Study Site, Windsor

H4G 3E7

Regeneron Study Site, Verdun

602 00

Regeneron Study Site, Brno

547 01

Regeneron Study Site, Náchod

702 00

Regeneron Study Site, Ostrava

130 00

Regeneron Study Site, Prague

04103

Regeneron Study Site, Leipzig

84-88

Regeneron Study Site, Budapest

409-3898

Regeneron Study Site, Chūō

734-8551

Regeneron Study Site, Hiroshima

252-0392

Regeneron Study Site, Kanagawa

602-8566

Regeneron Study Site, Kyoto

606-8507

Regeneron Study Site, Kyoto

420-8630

Regeneron Study Site, Shizuoka

430-0929

Regeneron Study Site, Shizuoka

641-8510

Regeneron Study Site, Wakayama

400-8506

Regeneron Study Site, Yamanashi

30-033

Regeneron Study Site, Krakow

90-436

Regeneron Study Site, Lodz

71-434

Regeneron Study Site, Szczecin

01-817

Regeneron Study Site, Warsaw

02-953

Regeneron Study Site, Warsaw

51-318

Regeneron Study Site, Wroclaw

51-685

Regeneron Study Site, Wroclaw

02841

Regeneron Study Site, Seoul

06591

Regeneron Study Site, Seoul

06973

Regeneron Study Site, Seoul

07441

Regeneron Study Site, Seoul

S10 2JF

Regeneron Study Site, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03738423 - Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter